Table 5 Parameter values for probabilistic sensitivity analysis

General

  Starting age

54

5

Normal

n/a

n/a

  % BSE at baseline

0.1

n/a

Beta

52.2

469.8

Quality of life

  Tx effectiveness probs—month 1

1

0.1

Lognormal

n/a

n/a

  Tx effectiveness probs—month 2 to 6

1

0.1

Lognormal

n/a

n/a

  Tx effectiveness probs—month 7 to 12

1

0.1

Lognormal

n/a

n/a

  Comp effectiveness probs—month 1

1

0.1

Lognormal

n/a

n/a

  Comp effectiveness probs—month 2 to 6

1

0.1

Lognormal

n/a

n/a

  Comp effectiveness probs—month 7 to 12

1

0.1

Lognormal

n/a

n/a

  Natural deterioration

0.00031

n/a

Beta

3.1

9996.9

Quality of life

  Utilities (all)

1

0.05

Normal

n/a

n/a

Costs

  Administration costs (all other treatments)

1

0.2

Gamma

25

0.04

  Follow up costs (all treatments)

1

0.2

Gamma

25

0.04

  Treatment visits year 1 (ranibizumab) BRVO

7.0

0.7

Gamma

100

0.07

  Treatment visits year 2 (ranibizumab) BRVO

2.1

0.21

Gamma

100

0.021

  Treatment visits year 1 (laser)

1.4

0.14

Gamma

100

0.014

  Treatment visits year 2 (laser)

0.3

0.03

Gamma

100

0.003

  Treatment visits year 1 (ranibizumab) CRVO

8.2

0.82

Gamma

100

0.082

  Treatment visits year 2 (ranibizumab) CRVO

3.5

0.35

Gamma

100

0.035